Reinerio Rodriguez, MD
Family Medicine · West New York, NJNPI 1174750772
Payments from drug & device makers
Across 440 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$706
- Novo Nordisk$675
- Amgen$605
- Pfizer$546
- Amarin Pharma, Inc.$487
- plus $4K from 32 others
What the payments were for
- Food & beverage$7,65099%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 61 | $1,094 |
| Boehringer Ingelheim | 51 | $706 |
| Novo Nordisk | 41 | $675 |
| Amgen(2 entities) | 44 | $605 |
| Pfizer | 38 | $546 |
| Amarin Pharma, Inc. | 27 | $487 |
| Merck | 25 | $412 |
| GSK | 25 | $392 |
| Lilly USA, LLC | 27 | $352 |
| Stryker | 3 | $338 |
| Exact Sciences | 5 | $299 |
| Gilead | 10 | $240 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $203 |
| AbbVie(2 entities) | 11 | $152 |
| Phathom Pharmaceuticals, Inc. | 3 | $143 |
| Johnson & Johnson | 8 | $130 |
| Medtronic | 1 | $113 |
| Penumbra, Inc. | 1 | $96 |
| Qiagen, LLC | 1 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $79 |
| Mylan Specialty L.p. | 5 | $75 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Eisai Inc. | 4 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Bayer | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Radius Health, Inc. | 2 | $27 |
| Genentech USA, Inc. | 2 | $25 |
| Ardelyx, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Intra-sana Laboratories | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cologuard Collection Kit$251
- MAKO$145
- FARXIGA$128
- BREZTRI AEROSPHERE$128
- SYMBICORT$128
- FASENRA$128
- VOQUEZNA$125
- Truvada$125
- Reveal LINQ$113
- STEGLATRO$113
How this compares
$7,695 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $150,790 |
| JardianceEmpagliflozin | 100 | $110,495 |
| JanuviaSitagliptin Phosphate | 88 | $90,445 |
| LinzessLinaclotide | 68 | $52,578 |
| EliquisApixaban | 30 | $45,915 |
| Diclofenac Sodium | 174 | $41,690 |
| TradjentaLinagliptin | 49 | $38,792 |
| VascepaIcosapent Ethyl | 51 | $35,699 |
| FarxigaDapagliflozin Propanediol | 32 | $34,035 |
| TrulicityDulaglutide | 31 | $33,951 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $28,462 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $23,919 |
| EntrestoSacubitril/Valsartan | 16 | $19,636 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $15,277 |
| MounjaroTirzepatide | 15 | $15,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $675 | $150,790112 claims |
| Boehringer IngelheimJardiance, Tradjenta | $706 | $149,287149 claims |
| MerckJanuvia, Janumet | $412 | $118,907126 claims |
| AbbVieLinzess | $152 | $52,57868 claims |
| AstraZenecaFarxiga, Lokelma | $1,094 | $49,31245 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $352 | $49,22246 claims |
| PfizerEliquis | $546 | $45,91530 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $392 | $38,61278 claims |
| NovartisEntresto | $14 | $19,63616 claims |
| Johnson & JohnsonXarelto | $130 | $13,37112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in West New York
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.